Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB668668,5-2,12
PKN64,7664,88-5,48
Msft0,13
Nokia4,68054,83851,20
IBM-0,33
Mercedes-Benz Group AG64,2464,27-0,11
PFE-0,33
03.12.2022 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 02.12.2022 17:30:40
Newron Pharma (NWRN.S, Swiss Exchange)
Závěr k 2.12.2022 Změna (%) Změna (CHF) Objem obchodů (CHF)
1,35 0,00 0,00 1 325
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 03.12.2022
Popis společnosti
Obecné informace
Název společnostiNewron Pharmaceuticals SpA
TickerNWRN
Kmenové akcie:Ordinary Shares
RICNWRN.S
ISINIT0004147952
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 25
Akcie v oběhu k 30.06.2022 17 845 345
MěnaEUR
Kontaktní informace
Ulicevia Ludovico Ariosto 21
MěstoBRESSO
PSČ20091
ZeměItaly
Kontatní osoba 
Funkce kontaktní osoby 
Telefon39 026 103 461
Fax390261034654

Business Summary: Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Newron Pharmaceuticals SpA revenues increased 6% to EUR2.8M. Net loss decreased 5% to EUR8.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expenses-other decrease of 25% to EUR3.5M (expense), Staff Costs in R&D decrease of 10% to EUR1.5M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations



  • Poslední aktualizace: 03.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorStefan Weber-
Vice President - FinanceRoberto Galli-01.01.2012
Vice President - Commercial AffairsDennis Dionne7001.01.201701.01.2017
Executive Vice President - Business DevelopmentMarco Caremi-
Chief Medical OfficerRavi Anand-